{"nctId":"NCT01386528","briefTitle":"Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B","startDateStruct":{"date":"2012-06-07","type":"ACTUAL"},"conditions":["Congenital Bleeding Disorder","Haemophilia B"],"count":13,"armGroups":[{"label":"Patients enrolled in trial","type":"EXPERIMENTAL","interventionNames":["Drug: nonacog beta pegol"]}],"interventions":[{"name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with haemophilia B with a FIX activity below or equal to 2%\n* Male patients with moderately severe or severe congenital haemophilia B with a FIX activity below or equal to 2% according to medical records\n* History of at least 150 exposure days to other FIX products\n* Scheduled major surgery\n\nExclusion Criteria:\n\n* Known history of FIX (coagulation factor nine) inhibitors based on existing medical records, laboratory report reviews and patient and LAR (legal acceptable representative) interviews\n* Current FIX (coagulation factor nine) inhibitors above or equal to 0.6 Bethesda Units (central laboratory)\n* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)\n* ALT (alanine aminotransferase) 3 times the upper limit of normal reference ranges at screening (central laboratory)\n* Immune modulating or chemotherapeutic medication","healthyVolunteers":false,"sex":"MALE","minimumAge":"13 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale (Excellent, Good, Moderate, Poor)","description":"Haemostatic effect during surgery was evaluated immediately after surgery (last stitch) using a fourpoint response scale:\n\n\\- Four-point response scale: Excellent, good, moderate, poor. The evaluation was done by the surgeon, anaesthesiologist and/or investigator based on experience as follows:\n\n1. Excellent: Better than expected/predicted in this type of procedure.\n2. Good: As expected in this type of procedure.\n3. Moderate: Less than optimal for the type of procedure but haemostatic response maintained without change of treatment regimen.\n4. Poor: Bleeding due to inadequate therapeutic response with adequate dosing, change of regimen required.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Consumption of NNC-0156-0000-0009 (U/kg Body Weight)","description":"Mean consumption of nonacog beta pegol (U/kg) used for treatment per patient before surgery, during surgery (the time from knife to skin until last stitch) and post-operative period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"328.2","spread":"113.1"}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements (Fulfilling Transfusion Criteria)","description":"Mean quantity of transfusion during surgery (the time from knife to skin until last stitch) and the postoperative period (Day 1-13).None of the patients required transfusions beyond Day 6 hence no values presented for days 7-13.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":"35.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"266.7","spread":"28.9"}]}]}]},{"type":"SECONDARY","title":"Haemoglobin Pre- and Post-surgery Start","description":"The mean pre-surgery and post surgery haemoglobin level.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.98","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.37","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.99","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events (AEs)","description":"The number of adverse events per patient years of exposure, reported during the trial period. Number is the only available option here, the data presented are rate of AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAE)","description":"The number of serious adverse events per patient years of exposure, reported during the trial period. Number is the only available option here, the data presented are rate of AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Inhibitors Against FIX (Coagulation Factor Nine)","description":"Number of patients with inhibitory antibodies","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Anaemia","Conjunctival haemorrhage","Epigastric discomfort","Excoriation","Face oedema"]}}}